Relmada Therapeutics, Inc. Common Stock (RLMD)
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company leverages its expertise in pain management and neuropharmacology to develop innovative drug candidates aimed at addressing unmet medical needs in chronic pain and related conditions.
Company News
Relmada Therapeutics strengthens its clinical advisory board by appointing Dr. Yair Lotan as Clinical Advisory Board Chair and Dr. Raj S. Pruthi as CMO-Urology, supporting the development of their NDV-01 program with a planned Phase 3 trial in H1 2026.
Relmada Therapeutics announced the discontinuation of its Reliance II and Relight Phase 3 studies for REL-1017 due to recent data monitoring committee evaluation. The company will continue to advance the Phase 1 study of REL-P11 and explore strategic alternatives to maximize shareholder value.
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Results from a human abuse potential study with REL-1017 exceeded expectations.